Clozapine monitoring at a specialised psychiatric hospital: A retrospective chart review

Background: Clozapine is the only Food and Drug Administration (FDA) and National Institute for Care and Excellence (NICE) approved drug for treatment-resistant schizophrenia (TRS). Its potentially life-threatening haematological side effects of neutropaenia and agranulocytosis mandate rigorous moni...

Cijeli opis

Bibliografski detalji
Glavni autori: Michelle V. Daniels, Suvira Ramlall
Format: Članak
Jezik:English
Izdano: AOSIS 2023-10-01
Serija:South African Journal of Psychiatry
Teme:
Online pristup:https://sajp.org.za/index.php/sajp/article/view/2039